Search

Your search keyword '"Laßmann, M."' showing total 517 results
Start Over Author "Laßmann, M."
517 results on '"Laßmann, M."'

8. Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT).

Author

Kratochwil, C., Fendler, W.P., Eiber, M., Hofman, M.S., Emmett, L., Calais, J., Osborne, J.R., Iravani, A., Koo, P., Lindenberg, L., Baum, R.P., Bozkurt, M.F., lgado Bolton, R.C. De, Ezziddin, S., Forrer, F., Hicks, R.J., Hope, T.A., Kabasakal, L., Konijnenberg, M., Kopka, K., Lassmann, M., Mottaghy, F.M., Oyen, W.J.G., Rahbar, K., Schoder, H., Virgolini, I., Bodei, L., Fanti, S., Haberkorn, U., Hermann, K., Kratochwil, C., Fendler, W.P., Eiber, M., Hofman, M.S., Emmett, L., Calais, J., Osborne, J.R., Iravani, A., Koo, P., Lindenberg, L., Baum, R.P., Bozkurt, M.F., lgado Bolton, R.C. De, Ezziddin, S., Forrer, F., Hicks, R.J., Hope, T.A., Kabasakal, L., Konijnenberg, M., Kopka, K., Lassmann, M., Mottaghy, F.M., Oyen, W.J.G., Rahbar, K., Schoder, H., Virgolini, I., Bodei, L., Fanti, S., Haberkorn, U., and Hermann, K.

Abstract

01 juli 2023, Contains fulltext : 294539.pdf (Publisher’s version ) (Open Access), Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already been obtained in early-phase studies using various combinations of targeting molecules and radiolabels. Definitive evidence of the safety and efficacy of [(177)Lu]Lu-PSMA-617 in combination with standard-of-care has been demonstrated in patients with metastatic castration-resistant prostate cancer, whose disease had progressed after or during at least one taxane regimen and at least one novel androgen-axis drug. Preliminary data suggest that (177)Lu-PSMA-radioligand therapy (RLT) also has high potential in additional clinical situations. Hence, the radiopharmaceuticals [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T are currently being evaluated in ongoing phase 3 trials. The purpose of this guideline is to assist nuclear medicine personnel, to select patients with highest potential to benefit from (177)Lu-PSMA-RLT, to perform the procedure in accordance with current best practice, and to prepare for possible side effects and their clinical management. We also provide expert advice, to identify those clinical situations which may justify the off-label use of [(177)Lu]Lu-PSMA-617 or other emerging ligands on an individual patient basis.

Published
2023

26. Standardization of administered activities in pediatric nuclear medicine: a report of the first Nuclear Medicine Global Initiative project, part 2 - current standards and the path toward global standardization

Author

Fahey, FH, Bom, HH-S, Chiti, A, Choi, YY, Huang, G, Lassmann, M, Laurin, N, Mut, F, Nunez-Miller, R, O'Keeffe, D, Pradhan, P, Scott, Andrew, Song, S, Soni, N, Uchiyama, M, and Vargas, Lucely

Subjects
Uncategorized
Abstract

The Nuclear Medicine Global Initiative (NMGI) was formed in 2012 and consists of 13 international organizations with direct involvement in nuclear medicine. The underlying objectives of the NMGI are to promote human health by advancing the field of nuclear medicine and molecular imaging, encourage global collaboration in education, and harmonize procedure guidelines and other policies that ultimately lead to improvements in quality and safety in the field throughout the world. For its first project, the NMGI decided to consider the issues involved in the standardization of administered activities in pediatric nuclear medicine. It was decided to divide the final report of this project into 2 parts. Part 1 was published in this journal in the spring of 2015. This article presents part 2 of the final report. It discusses current standards for administered activities in children and adolescents that have been developed by various professional organizations. It also presents an evaluation of the current practice of pediatric nuclear medicine specifically with regard to administered activities as determined by an international survey of 313 nuclear medicine clinics and centers from 29 countries. Lastly, it provides recommendations for a path toward global standardization of the administration of radiopharmaceuticals in children.

Published
2022
Full Text
View/download PDF

29. Additional file 1 of Biokinetics, dosimetry, and radiation risk in infants after 99mTc-MAG3 scans

Author

Soares Machado, J., Tran-Gia, J., Schlögl, S., Buck, A. K., and Lassmann, M.

Abstract

Patient-specific organ sizes classified per age groups (newborns and 1-year-olds). Table S2. Demographics clustered by age groups with patients’ information of age, gender, weight, body size, and injected activity. Table S3. The values for Patient organ-specific mean absorbed dose coefficients. Table S4. Mean organ-specific absorbed doses and respective estimated excess lifetime risk per cancer site (chances in 100,000 persons) for newborns (1.6–11.0 months) and 1-year-olds (13.0–20.0 months) clustered per gender. (PDF 1213 kb)

Published
2021
Full Text
View/download PDF

30. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy

Author

Konijnenberg, Mark, Herrmann, K, Kobe, C, Verburg, Frederik Anton, Hindorf, C, Hustinx, R, Lassmann, M, Konijnenberg, Mark, Herrmann, K, Kobe, C, Verburg, Frederik Anton, Hindorf, C, Hustinx, R, and Lassmann, M

Abstract

The EC Directive 2013/59/Euratom states in article 56 that exposures of target volumes in nuclear medicine treatments shall be individually planned and their delivery appropriately verified. The Directive also mentions that medical physics experts should always be appropriately involved in those treatments. Although it is obvious that, in nuclear medicine practice, every nuclear medicine physician and physicist should follow national rules and legislation, the EANM considered it necessary to provide guidance on how to interpret the Directive statements for nuclear medicine treatments. For this purpose, the EANM proposes to distinguish three levels in compliance to the optimization principle in the directive, inspired by the indication of levels in prescribing, recording and reporting of absorbed doses after radiotherapy defined by the International Commission on Radiation Units and Measurements (ICRU): Most nuclear medicine treatments currently applied in Europe are standardized. The minimum requirement for those treatments is ICRU level 1 (“activity-based prescription and patient-averaged dosimetry”), which is defined by administering the activity within 10% of the intended activity, typically according to the package insert or to the respective EANM guidelines, followed by verification of the therapy delivery, if applicable.Non-standardized treatments are essentially those in developmental phase or approved radiopharmaceuticals being used off-label with significantly (> 25% more than in the label) higher activities. These treatments should comply with ICRU level 2 (“activity-based prescription and patient-specific dosimetry”), which implies recording and reporting of the absorbed dose to organs at risk and optionally the absorbed dose to treatment regions.The EANM strongly encourages to foster research that eventually leads to treatment planning according to ICRU level 3 (“dosimetry-guided patient-specific prescription and verification”), whenever possible a

Published
2021

33. Joint Practice Guidelines for Radionuclide Lymphoscintigraphy for Sentinel Node Localization in Oral/Oropharyngeal Squamous Cell Carcinoma

Author

Alkureishi, L. W. T., Burak, Z., Alvarez, J. A., Ballinger, J., Bilde, A., Britten, A. J., Calabrese, L., Chiesa, C., Chiti, A., de Bree, R., Gray, H. W., Hunter, K., Kovacs, A. F., Lassmann, M., Leemans, C. R., Mamelle, G., McGurk, M., Mortensen, J., Poli, T., Shoaib, T., Sloan, P., Sorensen, J. A., Stoeckli, S. J., Thomsen, J. B., Trifiro, G., Werner, J., Ross, G. L., and The European Association of Nuclear Medicine (EANM) Oncology Committee and European Sentinel Node Biopsy Trial (SENT) Committee

Published
2009
Full Text
View/download PDF

38. Sentinel node in breast cancer procedural guidelines

Author

Buscombe, John, Paganelli, Giovanni, Burak, Zeynep E., Waddington, Wendy, Maublant, Jean, Prats, Enrique, Palmedo, Holger, Schillaci, Orazio, Maffioli, Lorenzo, Lassmann, M., Chiesa, Carlo, Bombardieri, Emilio, Chiti, Arturo, and On behalf of the European Association of Nuclear Medicine Oncology Committee and Dosimetry Committee

Published
2007
Full Text
View/download PDF

39. Developments in nuclear medicine – new radioisotopes in use and associated challenges: proceedings of a scientific seminar held in Luxembourg on 13 November 2019

Author

Laßmann, M., Neels, O., Sjögreen Gleisner, K., Bly, R., and Konijnenberg, M.

Subjects
Radiation protection, Energy research, Public health, Radiation exposure, Nuclear medicine, Conference proceedings, Nuclear accident
Abstract

The European Commission organises every year, in cooperation with the Group of Experts referred to in Article 31 of the Euratom Treaty, a scientific seminar on emerging issues in radiation protection – generally addressing new research findings with potential policy and/or regulatory implications. Leading scientists are invited to present the status of scientific knowledge in the selected topic. Based on the outcome of the scientific seminar, the Group of Experts referred to in Article 31 of the Euratom Treaty may recommend research, regulatory or legislative initiatives. The European Commission takes into account the conclusions of the Experts when setting up its radiation protection programme. The Experts' conclusions are valuable input to the process of reviewing and potentially revising European radiation protection legislation.

Published
2020

42. DNA damage and repair in peripheral blood mononuclear cells after internal ex vivo irradiation of patient blood with 131I.

Author

Schumann, S., Scherthan, H., Pfestroff, K., Schoof, S., Pfestroff, A., Hartrampf, P., Hasenauer, N., Buck, A. K., Luster, M., Port, M., Lassmann, M., and Eberlein, U.

Subjects
MONONUCLEAR leukocytes, THYROID gland tumors, RADIATION, IODINE radioisotopes, BLOOD cells, RESEARCH funding, RADIATION doses, DNA damage, BLOOD irradiation
Abstract

Aim: The aim of this study was to provide a systematic approach to characterize DNA damage induction and repair in isolated peripheral blood mononuclear cells (PBMCs) after internal ex vivo irradiation with [131I]NaI. In this approach, we tried to mimic ex vivo the irradiation of patient blood in the first hours after radioiodine therapy. Material and methods: Blood of 33 patients of two centres was collected immediately before radioiodine therapy of differentiated thyroid cancer (DTC) and split into two samples. One sample served as non-irradiated control. The second sample was exposed to ionizing radiation by adding 1 ml of [131I]NaI solution to 7 ml of blood, followed by incubation at 37 °C for 1 h. PBMCs of both samples were isolated, split in three parts each and (i) fixed in 70% ethanol and stored at − 20 °C directly (0 h) after irradiation, (ii) after 4 h and (iii) 24 h after irradiation and culture in RPMI medium. After immunofluorescence staining microscopically visible co-localizing γ-H2AX + 53BP1 foci were scored in 100 cells per sample as biomarkers for radiation-induced double-strand breaks (DSBs). Results: Thirty-two of 33 blood samples could be analysed. The mean absorbed dose to the blood in all irradiated samples was 50.1 ± 2.3 mGy. For all time points (0 h, 4 h, 24 h), the average number of γ-H2AX + 53BP1 foci per cell was significantly different when compared to baseline and the other time points. The average number of radiation-induced foci (RIF) per cell after irradiation was 0.72 ± 0.16 at t = 0 h, 0.26 ± 0.09 at t = 4 h and 0.04 ± 0.09 at t = 24 h. A monoexponential fit of the mean values of the three time points provided a decay rate of 0.25 ± 0.05 h−1, which is in good agreement with data obtained from external irradiation with γ- or X-rays. Conclusion: This study provides novel data about the ex vivo DSB repair in internally irradiated PBMCs of patients before radionuclide therapy. Our findings show, in a large patient sample, that efficient repair occurs after internal irradiation with 50 mGy absorbed dose, and that the induction and repair rate after 131I exposure is comparable to that of external irradiation with γ- or X-rays. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

49. Follow-Up of Low-Risk Differentiated Thyroid Cancer Patients Who Underwent Radioiodine Ablation of Postsurgical Thyroid Remnants after Either Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal

Author

Elisei, R, Schlumberger, M, Driedger, A, Reiners, C, Kloos, R T., Sherman, S I., Haugen, B, Corone, C, Molinaro, E, Grasso, L, Leboulleux, S, Rachinsky, I, Luster, M, Lassmann, M, Busaidy, N L., Wahl, R L., Pacini, F, Cho, S Y., Magner, J, Pinchera, A, and Ladenson, P W.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results